Key facts
- This page summarizes Peter W. Sonsini's Form 4 filing for Trevi Therapeutics, Inc. (TRVI).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Apr 2022, 17:26.
Peter W. Sonsini - 11 Apr 2022 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TRVI
- Reported as of
- 11 Apr 2022
- Net transaction value
- +$12,499,999
- SEC form
- 4
- Accepted by SEC
- 13 Apr 2022, 17:26:49 UTC
- Prior SEC filing
- 01 Feb 2022
- Next SEC filing
- 04 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/Louis Citron, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter W. Sonsini filed Form 4 for Trevi Therapeutics, Inc. (TRVI) on 13 Apr 2022.
Change
- Previous filing in this sequence was filed on 01 Feb 2022.
- Current net transaction value: +$12,499,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRVI
transaction
Common Stock
Purchase
- Transaction value
- $4,999,998
- Shares
- +2,631,578
- Change %
- +34%
- Price
- $1.90
- Shares after
- 10,421,428
- Date
- 11 Apr 2022
- Ownership
- See Note 2
- Footnotes
- F1, F2
TRVI
transaction
Common Stock
Purchase
- Transaction value
- $1,803,001
- Shares
- +948,948
- Change %
- Price
- $1.90
- Shares after
- 948,948
- Date
- 11 Apr 2022
- Ownership
- See Note 3
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRVI
transaction
Derivative
Pre-Funded Warrants
Purchase
- Transaction value
- $5,697,000
- Shares
- +3,000,000
- Change %
- Price
- $1.90
- Shares after
- 3,000,000
- Date
- 11 Apr 2022
- Ownership
- See Note 3
- Underlying class
- Common Stock
- Underlying amount
- 3,000,000
- Exercise price
- $0.001000
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Acquired from the Issuer on April 11, 2022 pursuant to a Securities Purchase Agreement dated April 6, 2022.
Footnote F2
The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest.
Footnote F3
The Reporting Person is a manager of NEA 18 VG GP, LLC, which is the sole general partner of NEA Partners 18 VG, L.P. ("NEA Partners 18 VG"). NEA Partners 18 VG is the sole general partner of NEA 18 Venture Growth Equity, L.P. ("NEA 18 VGE"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest.
Footnote F4
The Pre-Funded Warrants are exercisable immediately and will be exercisable until exercised in full. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 9.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise, which percentage may be increased or decreased at the holder's election upon 61 days' notice to the Issuer, not to exceed 19.99%.